News | August 06, 2012

Report Indicates Fate of Brachytherapy May Rest on Financial Benefits

August 6, 2012 — Brachytherapy offers an effective and relatively inexpensive method of treating internal cancers, and its popularity in the future will likely rely on its financial status, according to a new report by GlobalData.

The new report, Brachytherapy Devices - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018, suggests that the growing cost of cancer treatment has intensified focus on the cost-effectiveness of treatment approaches, and brachytherapy is perceived to be the best option.

Assessment of the costs and benefits of new and existing cancer treatment methods are essential for clinicians, payers and healthcare policymakers. Lifetime treatment costs for brachytherapy have been found to be nearly $3,000 lower than costs for radical prostatectomy in the treatment of low-risk prostate cancer, making it a high-value alternative. Data from U.S. patients newly diagnosed with prostate cancer over five and a half years revealed that brachytherapy was among the most cost-effective options, totaling a comparatively low $35,143.

The need for fewer treatments best serves patients who do not have local access to radiation treatment, cutting out lengthy journeys to an oncology center and representing significant cost savings for patients, as transportation costs constitute out-of-pocket expenses. Brachytherapy also saves money for healthcare systems, as lifetime treatment through brachytherapy costs substantially less than radical prostatectomy and intensity-modulated radiation therapy (IMRT).

Moreover, temporary brachytherapy is gaining popularity among both physicians and patients due to its ease of use as an outpatient procedure. Treatment is also shorter, and has a lower risk of serious adverse effects, making it altogether more likely for patients to conform to treatment schedules and refrain from wasting appointment times.

However, Medicare reimbursement cuts threaten the growth of the brachytherapy devices market in the United States, potentially removing brachytherapy from a huge portion of the global cancer patient population. The 2012 final Medicare Physician Fee Schedule (MPFS) saw Centers for Medicare and Medicaid Services (CMS) finalize proposals reducing Medicare payment rates for physicians by 27.4 percent for services in 2012. Earlier in 2010, the CMS under the MPFS-proposed rule implemented reimbursement cuts of 19 percent for radiation oncology. Based on these changes, it is estimated that radiation oncology, including brachytherapy, will experience an impact of negative 6 percent in 2012 and negative 10 percent in 2013.

For more information: www.globaldata.com

Related Content

more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment
News | Brachytherapy Systems | July 20, 2017
July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical
Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system

Elekta’s MR-linac integrates an advanced linear accelerator and a 1.5T magnetic resonance imaging (MRI) system. Combined, these systems will allow for simultaneous radiation therapy delivery and high-field MR tumor monitoring.

Feature | Radiation Oncology | July 05, 2017 | By Jeff Zagoudis
Image-guided radiation therapy offers great potential to improve the efficiency of treating cancer patients by more...

Photo courtesy of RaySearch

Feature | Treatment Planning | July 05, 2017 | By Jeff Zagoudis
While radiation oncologists have a number of proven techniques at their disposal for treating patients, the reality is...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Versa

Image courtesy of Elekta

News | Radiation Therapy | June 13, 2017
Radiation therapy (RT) using high-energy particles, like X-rays or electron beams, is a common and critical component...
News | Radiation Oncology | June 12, 2017
The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective radiotherapy...
stereotactic body radiation therapy (SBRT)
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017
The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body...
Sponsored Content | Case Study | Radiation Therapy | June 08, 2017
Stereotactic body radiation therapy (SBRT) employs significantly higher per fraction radiation doses than conventional...
pediatric imaging
News | Radiation Oncology | June 08, 2017
In an article published in the June 2017 issue of The Journal of Nuclear Medicine, researchers assert that e
Overlay Init